Skip navigation
Home
News
Products
about IR-World
Team
Customers
Partner
Contact
DE
EN
Communicators
are winners!
Text der Meldung
More News
15.11.2023
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
13.11.2023
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
06.11.2023
BioNxt Solutions Reports on Barcelona CPHI Conference
02.08.2023
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
15.05.2023
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
09.05.2023
BioNxt Successfully Completes Pilot Study for Contract Development Customer
24.04.2023
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
17.04.2023
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
07.03.2023
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
01.03.2023
BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
Previous
1
2
3
4
5
6
7
Next
Last